DALLAS, Feb. 11, 2013 /PRNewswire/ -- X-Change Corp (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is hemp extract-based cosmeceutical and nutraceutical solutions through its Phytiva brand product line, is proud to announce the appointment of internationally renowned cosmetic surgeon Steven B. Hopping, M.D., F.A.C.S. as Senior Medical Advisor, adding significant expertise to X-Change Corporation's team in skincare and other skin product indications, treatment, development, and sales.
Dr. Hopping, a Harvard-trained cosmetic surgeon who is certified by three surgical boards and serves as a Clinical Professor at The George Washington University School of Medicine, brings the Company more than twenty years of experience in the cosmetic surgery, cosmetic skin treatment, and brand-name and private-label skincare sectors through his long-established practice at both his Washington, DC Center for Cosmetic Surgery, and his surgical practice in Dubai, as well as through his proven leadership in the industry. For example, Dr. Hopping was elected by his peers as President of the American Academy of Cosmetic Surgery ("AACS") and of the American Academy of Cosmetic Surgery Foundation, among many other recognitions and achievements.
Robert Kane, President of X-Change Corp. stated, "It is a privilege and honor to announce the appointment of Dr. Steven B. Hopping as Senior Medical Advisor to the Company. Dr. Hopping's sterling reputation, proven expertise in skin and skincare-based medicine, and national and international prominence in strategically important industry sectors will serve well the X-Change Corp. and its Phytiva brand product line as the Company continues its rapid growth into cosmeceutical and nutraceutical solutions and markets around the world."
About Steven B. Hopping, M.D., F.A.C.S.
Dr. Steven B. Hopping received his specialty training at Harvard University and has been practicing cosmetic surgery for over 20 years, assisting patients across the United States and around the world. Dr. Hopping is Board Certified by three separate surgical boards: The American Board of Cosmetic Surgery, The American Board of Facial Plastic and Reconstructive Surgery, and The American Board of Otolaryngology, Head and Neck Surgery. He is also a Diplomate of the American Board of Hair Restoration. Dr. Hopping is the Medical Director of The Center for Cosmetic Surgery and of the Washington Hair Institute in Washington, DC. He also has an active practice in Dubai. Dr. Hopping is a Clinical Professor of Surgery at George Washington University and is regarded by his peers as a highly talented and innovative cosmetic surgeon. He lectures at numerous national and international conferences each year and is recognized around the world as both a leader and innovator in the cosmetic sector. Dr. Hopping has written numerous articles and been published in medical journals related to advances in cosmetic surgery, and is frequently sought out by the media as an authority in his field. Locally, Dr. Hopping is known for his philanthropy in supporting the arts, fighting poverty, and extending cosmetic surgery opportunities to the less fortunate.
Phytiva is the newly-launched brand that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a hemp-based product line, utilizing the unique and potent benefits of the hemp plant. Phytiva's revolutionary formulations target not just the symptom, but also the cause. Hemp is the ideal basis for healing solutions and has been utilized for centuries, as skin responds extremely well to its properties.
Phytiva strives to be one of the quintessential cosmeceutical and nutraceutical brands in the world. As cosmetics and nutrition are personal, over-the-counter markets, they continuously evolve with the introduction of new formulations and products, creating a multibillion-dollar global market. The company believes that Phytiva will capture a substantial and highly-profitable portion of that market, as Phytiva becomes a household name.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
President & CEO
SOURCE X-Change Corporation